Richard Jones

Richard Jones, the current CEO of Adrenomed AG, has a strong background in the biotech industry, including roles as CEO at various companies like BrYet Limited, Fusion Antibodies, and Holostem Terapie Avanzate S.r.l. Richard has also held senior leadership positions at Akcea Therapeutics and GSK, with a focus on commercialization, rare diseases, and oncology. Richard holds a PhD in Molecular Toxicology/Oncology from the University of Surrey.